Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

10/12/23 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SGEN alert in real time by email

Seagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.

Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call.

About Seagen

Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is headquartered in Bothell, Washington and has locations in California, Canada, Switzerland and across Europe. For additional information, visit www.seagen.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012765576/en/

Get the next $SGEN alert in real time by email

Date	Price Target	Rating	Analyst
2/16/2023	$140.00 → $175.00	In-line → Outperform	Evercore ISI
2/16/2023	$155.00 → $175.00	Outperform → Strong Buy	Raymond James
2/6/2023	$162.00 → $141.00	Outperform → Market Perform	SVB Securities
11/21/2022	$135.00	Hold	Truist
10/11/2022	$177.00 → $178.00	Market Perform → Outperform	BMO Capital Markets
6/29/2022	$220.00	Outperform	Raymond James
6/24/2022	$169.00	Market Perform	BMO Capital Markets
2/16/2022	$201.00 → $142.00	Market Outperform	JMP Securities

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

Chat with this insight

Recent Analyst Ratings for
$SGEN

$SGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Seagen upgraded by Evercore ISI with a new price target

Seagen upgraded by Raymond James with a new price target

Seagen downgraded by SVB Securities with a new price target

$SGEN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

Chat with this insight

Recent Analyst Ratings for $SGEN

$SGEN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Seagen upgraded by Evercore ISI with a new price target

Seagen upgraded by Raymond James with a new price target

Seagen downgraded by SVB Securities with a new price target

$SGEN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Recent Analyst Ratings for
$SGEN

$SGEN
Analyst Ratings

$SGEN
Insider Trading